- May 9, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Myocet, Adriamycin, Caelyx, Rubex
Synonyms :
Class :
Dosage form & Strength:
Injectable solution:
2mg/ml
Powder for injection:
10mg,
50mg
Note: Antiemetics are recommended to prevent side effects such as nausea and vomiting. Doxorubicin is more responsive to some cancers than others, always consult institutional protocol for therapy. Prefer a lower dose in the recommended dose range or a longer interval between cycles for pre-treated patients.
Lifetime cumulative doses of more than 550 mg/m2 are associated with myocardial damage including acute left ventricular failure.
acute lymphoblastic leukemia(All)
50
mg/m^2
Intravenous (IV)
once in a 21- or 28-day course in combination with cyclophosphamide, vincristine, and dexamethasone.
30 mg/m2 IV on days 1, 8, and 15 of the 8-week cycle in combination with cyclophosphamide, thioguanine, vincristine, and cytarabine.
Single drug-treatment:
60 - 75
mg/m^2
Intravenous (IV)
over 3 to 10 minutes once in 21 days for 4 cycles.
Combination drug-treatment: 30 to 60 mg/m2 IV once every 21 to 28 days in combination with cyclophosphamide, fluorouracil, and docetaxel.
30
mg/m^2
Intravenous (IV)
on day 2 in the 14-day course in combination with methotrexate, cisplatin, and growth factor supporter.
MAVC regimen: 30 mg/m2 IV on day 2 in the 28-course in combination with methotrexate, vinblastine, and cisplatin for up to 6 cycles.
Single drug-treatment:
60 - 75
mg/m^2
Intravenous (IV)
over 3 to 10 minutes every 21 days.
Combination drug treatment: 40 to 75 mg/m^2 IV every 21 to 28 days in combination with other chemotherapeutic agents.
CTACE intra-arterial:
50 - 75
mg/m^2
Intravenous (IV)
as a single dose via intra-arterial injection every 2 months for a maximum of 3 doses.
DEB-TACE intra-arterial: 150 mg administered via loaded drug-eluting bead every 2 months for a maximum of 3 doses.
Single dose regimen:
60 - 75
mg/m^2
Intravenous (IV)
over 3 to 10 minutes once in 21 days.
Combination regimen: 25 mg/m^2 IV on days 1 and 15 every 28 days in combination with bleomycin, vinblastine, and dacarbazine for 2 to 4 cycles.
50
mg/m^2
Intravenous (IV)
on day 1 of the 14-day course in combination with gemcitabine and growth factor supporter.
45
mg/m^2
Intravenous (IV)
on day 1 every 21 days in combination with cyclophosphamide and vincristine.
50
mg/m^2
Intravenous (IV)
on day 1 every 21 days in combination with cyclophosphamide, vincristine, and prednisone.
PAD regimen:
9
mg/m^2
Intravenous (IV)
on days 1 to 4 for 3 cycles in combination with bortezomib and dexamethasone.
VDT-PACE regimen: 10 mg/m^2 continuous infusion on days 1 to 4 of each cycle (in combination with bortezomib, dexamethasone, thalidomide, cisplatin, cyclophosphamide, and etoposide).
50
mg/m^2
Intravenous (IV)
on day 1 every 21 days in combination with cisplatin and cyclophosphamide.
Uterine sarcoma:
60
mg/m^2
Intravenous (IV)
on day 1 every 21 days either as a single agent or in combination with dacarbazine.
Dosage form & Strength:
Injectable solution:
2mg/ml
Powder for injection:
10mg,
50mg
Note: Antiemetics are recommended to prevent side effects such as nausea and vomiting. Doxorubicin is more responsive to some cancers than others, always consult institutional protocol for therapy. Prefer a lower dose in the recommended dose range or a longer interval between cycles for pre-treated patients.
Lifetime cumulative doses of more than 550 mg/m2 are associated with myocardial damage including acute left ventricular failure.
acute lymphoblastic leukemia(All)
30
mg/m^2
Intravenous (IV)
per day on days 0 and 1 of a 4-week cycle in combination with dexrazoxane, vincristine, methotrexate, cytarabine.
CNS therapy for high-risk patients: 30 mg/m2 per day of a 3-week cycle in combination with dexrazoxane, vincristine, mercaptopurine, and cytarabine.
75
mg/m^2
Intravenous (IV)
per day on day 1 every 21 days for 5 cycles in combination with vincristine and cyclophosphamide.
Regimen B for Stage I, II, III, IV:
20
mg/m^2
Intravenous (IV)
per day administered as a continuous infusion for days in combination with cisplatin.
Regimen C for Stage I: 20 mg/m2 per day on days 1, 2, and 3 every 3 weeks for 4 cycles.
50
mg/m^2
Intravenous (IV)
per day on day 1 of a 21-day cycle in combination with vincristine, prednisone, and cyclophosphamide.
25 mg/m^2 per day on days 1 and 2 of a 21-day cycle in combination with vincristine, prednisone, and cyclophosphamide.
For advanced-stage ABVD regimen: 25 mg/m^2 per day on days 0 and 14 of a 28-day cycle in combination with bleomycin, vinblastine, and dacarbazine.
< 12 kg:
0.83
mg/kg
Intravenous (IV)
per day as a continuous infusion on days 1, 2, and 3 of a total dose of 2.49 mg/kg in combination with cyclophosphamide and vincristine with etoposide and cisplatin.
> 12 kg: 25 mg/m^2 per day as a continuous infusion on days 1, 2, and 3 of a total dose of 75 mg/m2 in combination with cyclophosphamide and vincristine with etoposide and cisplatin.
25
mg/m^2
Intravenous (IV)
per day infused over 1 hour on days 4 and 5 of a 21- to 28- day cycle in combination with cyclophosphamide, prednisone, methotrexate, and vincristine (dose adjustment may depend on neutrophil recovery).
measles, mumps, rubella, and varicella vaccine, live (Rx)
may diminish the therapeutic effect
measles mumps and rubella vaccine, live
may diminish the therapeutic effect
may diminish the therapeutic effect
smallpox (vaccinia) vaccine, live
may diminish the therapeutic effect
may diminish the therapeutic effect
measles, mumps, rubella, and varicella vaccine, live (Rx)
may diminish the therapeutic effect
measles mumps and rubella vaccine, live
may diminish the therapeutic effect
may diminish the therapeutic effect
smallpox (vaccinia) vaccine, live
may diminish the therapeutic effect
may diminish the therapeutic effect
may decrease the therapeutic effect when combined
may enhance the immunosuppressive effect of immunosuppressants
may enhance the immunosuppressive effect of immunosuppressants
may enhance the immunosuppressive effect of immunosuppressants
may enhance the immunosuppressive effect of immunosuppressants
may enhance the immunosuppressive effect of immunosuppressants
may enhance the immunosuppressive effect of immunosuppressants
may enhance the immunosuppressive effect of immunosuppressants
may enhance the immunosuppressive effect of immunosuppressants
may enhance the immunosuppressive effect of immunosuppressants
immunosuppressants such as doxorubicin may enhance the immunosuppressive effect of another drug
immunosuppressants such as doxorubicin may enhance the immunosuppressive effect of another drug
immunosuppressants such as doxorubicin may enhance the immunosuppressive effect of another drug
immunosuppressants such as doxorubicin may enhance the immunosuppressive effect of another drug
immunosuppressants such as doxorubicin may enhance the immunosuppressive effect of another drug l
the combination with doxorubicin may decrease the therapeutic effects of another drug
the combination with doxorubicin may decrease the therapeutic effects of another drug
may enhance the hepatotoxic effect of mercaptopurine
may increase serum concentrations of doxorubicin
the effect of doxorubicin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
P-glycoprotein inhibitors or ABCB1 inhibitors increase the concentration of doxorubicin in serum
CYP2D6 Inhibitors increase the concentration of doxorubicin in serum
CYP2D6 Inhibitors increase the concentration of doxorubicin in serum
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may enhance the serum concentration
may enhance the serum concentrations of CYP2D6 inhibitors
may enhance the serum concentration of P-glycoprotein/ABCB1 inhibitors
immunosuppressants may decrease the therapeutic effect of live and attenuated vaccines
immunosuppressants may decrease the therapeutic effect of live and attenuated vaccines
immunosuppressants may decrease the therapeutic effect of live and attenuated vaccines
immunosuppressants may decrease the therapeutic effect of live and attenuated vaccines
immunosuppressants may decrease the therapeutic effect of live and attenuated vaccines
immunosuppressants may decrease the therapeutic effect of live and attenuated vaccines
may enhance the myelosuppressive effect
may increase the serum concentration of CYP2D6 substrates
may increase the serum concentration of CYP2D6 substrates
may increase the serum concentration of CYP2D6 substrates
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
It may enhance the effect when combined with lonafarnib by affecting the P-glycoprotein efflux transporter
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
It may enhance the effect when combined with tafamidis meglumine
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
It may enhance the risk of adverse effects when combined with vitamins
may manifest acute “recall” pneumonitis after radiation therapy
may manifest acute “recall” pneumonitis after radiation therapy
may increase the risk of cardiotoxicity
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may reduce the therapeutic effect of typhoid Vaccine
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may decrease the serum concentration
may decrease the serum concentration
